Work & Theory on February 23, 2026

Guardant buys MetaSight for $59M upfront to acquire blood test tech

HomeUncategorized Guardant buys MetaSight for $59M upfront to acquire blood test tech
Uncategorized
1 Min Read

MetaSight uses metabolomics, lipidomics and proteomics mass spectrometry technologies to develop tests for specific diseases, including conditions outside of oncology.

Continue reading →

Work & Theory on February 23, 2026 Uncategorized

Leave a comment

Your email address will not be published. Required fields are marked *

let’s talk
Get in Touch

Stay up-to-date with the latest releases.

Facebook X-twitter Instagram Linkedin Youtube

© 2025 — AGNO by GT3Themes. All Rights Reserved.

Back to top